Skip to main content

Table 1 Characteristics of 5 lung transplant recipients patients with posttransplant lymphoproliferative disorder (PTLD).

From: Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients

Pt. #, age, sex

Underlying disease

Date of TX

Type of TX

Onset of PTLD

Immuno suppressive

treatment (dosage)

PTLD description

EBV DNA copies/105PBMC

1, 29, M

cystic fibrosis

Dec. 2000

double-lung

May 2003

Ciclosporin (350 mg/die)

Steroid (5 mg/die)

Laterocervical HL

1,760

2, 25, F

cystic fibrosis

Sep. 2001

double-lung

May 2002

Ciclosporin (150 mg/die)

Steroid (40 mg/die)

Mediastinic large B-cells NHL

< 10

3, 53, M

sarcoidosis

Dec. 2001

single-lung

Nov. 2002

Ciclosporin (250 mg/die)

Steroid (25 mg/die)

Mediastinic large B-cells NHL

< 10

4, 39, M

Istiocytosis X

Dec. 2004

double-lung

May 2005

Ciclosporin (550 mg/die)

Steroid (5 mg/die)

thoracic localization of EBV-positive B-cell lymphoma.

307

5, 63, M

Idiopathic pulmonary fibrosis

Aug. 2006

double-lung

Dec. 2006

Ciclosporin (300 mg/die)

Steroid (20 mg/die)

Mycophenolate mofetil (1000 mg/die)

Single nodule in lower left lobe, double mediastinic nodule (at histology, no tumor markers)

751,000 EBV DNA copies/μg tissue DNA, 8,500,000 copies/ml BAL

15, 289

  1. TX: transplantation; PBMC: peripheral blood mononuclear cells; M: male; F: female; HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma.